John Smither Sells 1,600 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director John Smither sold 1,600 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $25.32, for a total transaction of $40,512.00. Following the transaction, the director owned 8,760 shares of the company’s stock, valued at approximately $221,803.20. The trade was a 15.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMS opened at $21.86 on Friday. The firm’s fifty day moving average is $28.84 and its 200-day moving average is $31.27. NewAmsterdam Pharma Company N.V. has a 52 week low of $21.80 and a 52 week high of $42.21. The firm has a market cap of $2.61 billion, a P/E ratio of -10.12 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Key NewAmsterdam Pharma News

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $52 price target. Other analysts also maintain positive views, including BMO Capital Markets at $58, Jefferies at $45 and RBC at $50, supporting the longer-term outlook for NAMS. HC Wainwright rating report
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests short selling is not a meaningful explanation for the recent decline, although the data may reflect an incomplete or anomalous report. NewAmsterdam Pharma market data
• Neutral Sentiment: Analyst reports discussing NAMS alongside Amgen, Dyne Therapeutics and Ionis Pharmaceuticals did not identify a new company-specific catalyst. Broader healthcare-sector commentary may influence sentiment but provides limited direct information about NewAmsterdam’s business. Healthcare analyst report
• Negative Sentiment: Director John W. Smither sold 1,600 shares for approximately $40,512, reducing his direct holdings by 15.44%. Although the sale may have been for personal reasons, it can reinforce investor caution during a period of market weakness. SEC insider transaction filing
• Negative Sentiment: NAMS reached a new one-year low following the insider-sale disclosure, signaling continued technical and investor-pressure concerns. The company also remains loss-making; its latest quarterly EPS missed expectations, and analysts forecast a full-year loss of about $1.82 per share. New one-year low report

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Geode Capital Management LLC raised its stake in NewAmsterdam Pharma by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after buying an additional 437 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares in the last quarter. AlphaCentric Advisors LLC boosted its holdings in NewAmsterdam Pharma by 6.7% in the first quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock worth $469,000 after acquiring an additional 925 shares in the last quarter. Finally, KBC Group NV acquired a new stake in NewAmsterdam Pharma in the first quarter valued at approximately $37,000. 89.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

NAMS has been the subject of several research analyst reports. BMO Capital Markets began coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Royal Bank Of Canada decreased their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.73.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.